GlobalData on MSN1d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
The American Journal of Managed Care3d
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
Medscape13d
Young Woman’s Stroke Linked to Hormonal Contraceptives
There was no history of seizures, head trauma, recent surgery, prolonged immobilisation, or known hypercoagulable disorders ... the potential risks of future thrombotic events, especially in ...
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...
The Financial Express2d
USFDA approves novel treatment for Hemophilia; Medication can be given up to once every 2 months
Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...
Medical Dialogues12h
FDA Approves fitusiran for Hemophilia A and B
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
PharmExec1d
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
GEN - Genetic Engineering and Biotechnology News1d
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.